Browse Articles
Discover research articles across all indexed journals
Computational pathology–based classifier for predicting Gleason grade group upgrading on radical prostatectomy from diagnostic biopsies.
329 Background: Prostate biopsy is the gold standard for diagnosing and risk stratification of prostate cancer. As therapeutic options expand, detailed biopsy analysis becomes critical. However, discrepancies between biopsy samples and radical prostatectomy (RP) Gleason grade groups occur, with about 30% of patients experiencing an upgrade. This inconsistency can lead clinicians to underestimate disease severity, impacting patient management and outcomes. This study aimed to identify patients likely to experience a Gleason grade group upgrade (GGU) at RP by utilizing an AI-based computational pathology model that analyzes spatial architecture of lymphocytes from baseline diagnostic biopsies. Methods: We retrospectively analyzed whole-slide images from diagnostic biopsies of 128 patients who underwent RP (29 upgraded) at Helsinki University Hospital. Patients were randomly divided into training (D 1 ) and test (D 2 ) sets, comprising 89 and 39 patients, respectively. Nuclei segmentation and classification were performed using a deep learning model, followed by the extraction of 350 features representing the spatial interactions between lymphocytes and other nuclei. Feature selection and hyperparameter tuning were conducted on D 1 using cross-validated decision trees. The top five features and optimal parameters were then used to fit a final model GUP (Gleason Upgrade Predictor) on D 1 . GUP was subsequently used to predict GGU on D 2 . For comparative analysis, we developed models M c , M p and M cp using clinical variables (age, blood PSA level, PSA doubling time, T-stage, comorbidity index), data on proportion of Gleason grade patterns in the biopsies, and their combination. Finally, we integrated clinical variables into GUP (GUP c ) to evaluate whether this combination would enhance predictive performance and improve explainability. Results: The top five features measure lymphocyte cluster irregularity and their interactions with other cells. GUP achieved an AUC of 0.83 (±0.08), outperforming models trained exclusively on clinical data, Gleason pattern proportions, or their combination. Notably, GUP’s performance further improved when it was integrated with clinical variables (AUC 0.87 ± 0.1; Table). Conclusions: Our AI-driven computational pathology model shows strong predictive performance for GGU. Although external validation is still required, this model holds promise for improving the accuracy of Gleason group assessments at diagnosis. Model performance comparison. Model AUC ± std Balanced ACC GUP: Top 5 features of lymphocyte spatial architecture 0.83 ± 0.08 0.83 M c : Clinical variables 0.58* ± 0.08 0.58 M p : Pathological annotations of Gleason patterns 0.55* ± 0.10 0.52 M cp : M c + M p 0.72* ± 0.11 0.72 GUP c : GUP + clinical data 0.87 ± 0.10 0.87 *Indicates a statistically significant value at p < 0.05 comparing the model to GUP c .
Genome-scale metabolic reconstruction of urinary microbiome: Pathway for personalized medicine.
822 Background: The human microbiome significantly influences the efficacy and safety of various medications. To integrate microbial metabolism into precision medicine, it is crucial to develop strain- and molecule-specific computational models that can predict a patient's microbiome's ability to metabolize chemotherapy drugs. This study evaluates the potential of urine, pellet, and supernatant samples to identify microbial profiles and metabolizing genes in patients with bladder cancer. Methods: Catheterized urine, pellet, and supernatant samples from six patients (5 males and 1 female) with bladder cancer were analyzed to identify microbial species and strains, assess drug gene abundance, and predict drug metabolism. Whole-genome sequencing (WGS) was performed, and gene annotation was conducted using the PubSEED platform. Biosynthetic pathways were identified following the KEGG PATHWAY resource, and AGORA2 reconstruction was used for final metabolic reactions. Results: WGS revealed a diverse microbial community, with 1,024 species unique to urine, 386 unique to pellet, and 1,861 species common to both. The most prevalent species, Enterococcus faecalis and Staphylococcus epidermidis, accounted for over 60% of the microbial population in both urine and pellet samples. A detailed comparison of OTU abundance between paired urine and pellet samples showed significant variations in microbial composition, yet a strong correlation between the two sample types. The net metabolizing capacity of 13 chemotherapy-drug metabolites was assessed among the six patients. Mean flux calculations indicated highly variable metabolism of gemcitabine (median 773.57, IQR 380-1056), SN38 (irinotecan) (median 770.24, IQR 10.1-2234.5), and bile salt hydrolase (median 130.80, IQR 9.8-318.2). These findings highlight the microbiome's extensive role in influencing chemotherapy drug pharmacokinetics. Conclusions: This study demonstrates the potential of microbiome profiling in informing precision medicine, suggesting that microbiome modification could enhance chemotherapy drug pharmacokinetics and improve patient outcomes. Further research is needed to validate these findings and refine microbiome-based precision medicine in oncology.
Neoadjuvant pembrolizumab (pembro) and accelerated methotrexate, vinblastine, doxorubicin, cisplatin (aMVAC) in non-urothelial (non-UC) histologic subtype muscle invasive bladder cancer (MIBC): A phase 2 trial.
769 Background: Cisplatin-based chemotherapy (CT) prior to radical cystectomy (RC) + perioperative anti-PDL1 improves pathologic complete response rates (pCR) and survival in MIBC with predominant UC. Outcomes are poorer in the 5-10% of MIBC with pure/predominant non-UC histology. Thus, optimizing neoadjuvant therapy for these patients (pts) is critical. Pembro monotherapy has induced promising pCR rates in histologic subtypes (PURE-01 trial). We hypothesized that aMVAC + pembro would be safe and effective for non-UC MIBC and conducted a single-center trial testing this combination in pts with pure/predominant non-UC MIBC. Methods: Pts with resectable MIBC (cT2-4a/N0-1) with pure/predominant non-UC histology and fit for CT and RC were treated with neoadjuvant pembro (200mg q3 weeks x 3) + aMVAC (q2 weeks x 4) with G-CSF. Primary endpoint was pCR rate. Secondary endpoints included toxicity, pathologic downstaging (<ypT2N0), and event-free and overall survival (EFS, OS) from initiation of neoadjuvant therapy. EFS/OS were estimated using Kaplan-Meier method. A single arm phase II trial with 91% exact power to rule out 8% pCR rate at 1-sided 4% level, if true pCR rate was 36%, required 17 pts. If ≥4/17 had pCR, then an 8% pCR rate was rejected. Results: 17 pts were enrolled from 3/2020 to 3/2024 (Table). Median age was 60 (range 39-74); 12 were male, 5 female. Predominant histologies at TURBT were squamous (5), plasmacytoid (3), micropapillary (3), poorly differentiated (3), glandular (2), and sarcomatoid (1). 4 pts discontinued treatment (2 toxicity, 1 patient choice, 1 unrelated illness), of whom 2 completed 3 planned pembro doses. Median time to RC from completing neoadjuvant therapy was 6 weeks (range 4-24); 2/17 pts did not proceed to RC, 1 (squamous) due to clinical status (achieved clinical CR and remained recurrence-free) and 1 (micropapillary) deemed to have unresectable MIBC. 9/17 patients (53%) achieved pCR; 1 patient achieved ypTisN0 (downstaging 59%). With median follow-up of 29 months the estimated 2-year OS was 75% (95%CI: 40-91) and estimated 2-year EFS was 69% (95%CI: 36-88). Median OS was not reached; estimated median EFS was 38 months (95%CI: 12, NR). Conclusions: The primary endpoint was met: pCR and downstaging rates with neoadjuvant aMVAC + pembro were significantly higher than reported historically in pts with pure/predominant non-UC MIBC. EFS/OS were also encouraging. No new safety signal was noted; all but 2 pts underwent RC. Correlative analysis for putative biomarkers, using tissue, blood and urine biospecimens, is ongoing. Clinical trial information: NCT04383743 . Baseline and Treatment Characteristics N(%) Clinical T-Stage at diagnosis T2 10 (59) T3-4 * 7 (41) aMVAC Cycles 4 cycles + 13 (76) <4 cycles 4 (24) Pembro Cycles 3 cycles 15 (88) <3 cycles 2 (12) * 1 patient with cN1 (T4a); + 1 patient had dose reduction.
First preliminary results of artificial intelligence-generated, explainable treatment recommendations for renal cell cancer based on multidisciplinary cancer conferences.
465 Background: The expert panel in multidisciplinary cancer conferences (MCC) decides on the best available treatment for the individual cancer patient. To support these complex evidence-based decisions, an artificial intelligence (AI) was developed to generate treatment recommendations for renal cell cancer (RCC) patients to support decision-making in MCC. Methods: We have transformed comprehensive patient data (99 individual machine-readable features) of 880 MCC recommendations for RCC from the years 2015 - 2022 into representations that can be used in software development. We developed a two-step process in order to train classifiers to mimic MMC recommendations. First, we identified superordinate categories of the recommendations. Afterwards, we specified the detailed recommendation. For this purpose, we used different machine learning (CatBoost, XGBoost, Random Forest) and deep learning (SoftOrdering-1d-CNN) approaches with 787 training cases and 93 test set cases. Accuracy weights are determined by F1-Score. Results: The KITTU-AI is able to generate fully automated treatment recommendations for patients with histologically confirmed RCC in MCC. First, the AI can decide which kind of superordinate recommendation should be applied, e.g. surgery or anticancer-drugs (Table). Second, our AI system is able to suggest the specific surgical treatment as well as the correct drugs (Table). The AI-generated recommendation is presented explainable based on the clinical features and their importance score. Conclusions: To our knowledge, we present the first time data for fully automated AI-based treatment recommendations for MMC in RCC with promising accuracy rates.Our selected AI architecture is able to learn and to generate medically comprehensible and explainable treatment recommendations. Small numbers of recommended therapies hamper AI training but this will improve with increasing numbers over time. Next, clinical trial data will be implemented to enable a higher level of explainability. Meanwhile, the first prospective validation is ongoing. Accuracy rates for AI-generated treatment recommendations of renal cell cancer based on F1-scores (test set of 93 cases). Task (number) F1-Score ↑ #Classes Class (number) F1-Score High Level Prediction (93) 0.76 (CatBoost) 5 Surgery (10)Medication (45)Aftercare (22)Best supportive care (4)Radiotherapy (12) 0.450.920.880.000.47 Low Level Surgical Prediction (10) 0.81(Soft Ordering) 3 Primary tumor resection (4)Resection of recurrent tumor (1)Metastases resection (5) 0.670.000.73 Low LevelDrug Prediction (45) 0.73 (XGBoost) 8 Sunitinib (8)Nivolumab (7)Cabozantinib (6)Pembrolizumab/Axitinib (5)Nivolumab/Ipilimumab (4)Pazopanib (3)Pembrolizumab (3)Other (9) 0.520.780.400.890.601.001.000.67
Investigating clinical associations between genomic alterations and prostate cancer lineage states using circulating tumor cell RNA sequencing.
256 Background: Resistance to Androgen Receptor Pathway Inhibitors (ARPI) in metastatic prostate cancer (mPC) is universal and can be driven by complex genomic alterations. The evolution of lineage state transitions from adenocarcinomas to neuroendocrine prostate cancer (NEPC) has also been shown to drive treatment resistance and poor survival. Identifying the timing and association of genomic mutations with lineage state transitions has been limited by the need for serial tumor biopsies. We report an integrated analysis of clinical next-generation sequencing (NGS) data and mPC lineage states with a novel circulating tumor cell (CTC) RNA sequencing methodology. Methods: We collected 273 samples from 117 unique patients with mPC in a prospective biomarker trial. CTCs were purified via immunomagnetic capture on an automated microfluidic technology and analyzed via RNA-seq. A subset of patients had a clinical grade genetic test performed on a contemporary metastatic tissue biopsy. We compared CTC gene expression for lineage states (luminal A, luminal B, NEPC) with somatic gene mutation subtypes known to confer resistance to ARPIs (AR, p53, RB, PTEN, HRR genes) and overall survival (OS). Results: Single sample pathway analysis of high CTC purity samples identified four transcriptional phenotypes: luminal A-like (LumA), luminal B-like (LumB), low proliferation (LP), and neuroendocrine (NE). Compared to patients with low CTC burden/purity (median OS not reached), patients with LumA and LP phenotypes had similar survival, patients with LumB and NE CTC phenotypes had shorter survival (LumB: median OS 6m, HR 9.1 [3.8-21.8], p<0.0001, NE: median OS 3.7m, HR 11.8 [2.4-57.2], p=0.0019). AR alterations were found in samples with prior ARPI exposure and at similar frequencies across all CTC phenotypes but NE where they were absent. RB mutations were enriched in the unfavorable CTC phenotypes (LumB, NE; p=0.0288). Integrating CTC phenotype with presence or absence of at least one high risk genomic alteration (AR, RB, TP53, PTEN), patients with favorable CTC phenotype (Low burden, LP and LumA) and no high risk alterations had the longest median survival (median OS NR), followed by patients with favorable phenotype but a high risk alteration (median OS 12.7m), patients with an unfavorable phenotype (LumB, NE) but no high risk alteration (median OS 8m), and unfavorable phenotype with a high risk alteration (median OS 4m). Conclusions: Somatic mutations in mCRPC influence lineage state acquisitions and treatment resistance. Lineage state transitions themselves are associated with poor outcomes and decreased survival which is worsened in the presence of high-risk genetic mutations including RB. This data presents potentially targetable patient populations that would benefit from treatment intensification and early disease monitoring for more aggressive mCRPC subtypes.
Safety of combining radiotherapy and antibody drug conjugates in advanced urothelial and other cancers.
758 Background: Antibody drug conjugates (ADCs) such as enfortumab vedotin (EV) and sacituzumab govitecan (SG) are novel treatments increasingly used for metastatic urothelial carcinoma (mUC). SG is also utilized in metastatic breast cancer (mBC). Radiotherapy (RT) is used for palliation or consolidation of metastatic sites in mUC and for bladder preservation in localized disease. There is limited data evaluating the safety of ADCs when combined with RT. We sought to characterize the safety of RT in patients with mUC or mBC cancer receiving EV or SG. Methods: A bi-institutional retrospective analysis was performed. Eligible patients had a diagnosis of mUC or mBC and received RT within 6 months of EV or SG receipt. Patients were stratified by intensity of RT (higher vs. lower), site of RT (pelvis with bladder, pelvis without bladder, outside pelvis), and RT timing relative to ADC (prior to, within 4 weeks of, or after ADC infusion). ADC status was categorized as discontinued for progression of disease, discontinued for toxicity, or continued therapy. Those who discontinued ADC for toxicity were further evaluated to assess attribution to RT vs. expected treatment-limited toxicity of ADC. Results: Between January 1, 2020 and January 31, 2024, 103 patients received 166 RT courses within 6 months of ADC. RT courses were of mostly lower intensity (66%) vs. higher intensity (34%), using a cutoff of biologically equivalent dose (a/b=10) of 35Gy after assessing the distribution of RT regimens. RT location was extra-pelvic (58%), pelvis without bladder (16%), brain (14%), and pelvis with bladder (11%). RT delivery occurred prior to ADC (30%), concurrent with ADC (46%), or after ADC completion (24%). Of 77 RT courses concurrent with ADC, 10 (13%) patients experienced grade 3-5 toxicity. All of these were attributed to known ADC toxicities and only one possibly influenced by addition of RT. No patients receiving RT to the bladder experienced high-grade toxicity. Conclusions: This real world, retrospective study thus found no added safety events for patients receiving RT with ADCs, even when administered concurrently. Further data to validate these findings is needed as the use of both ADCs and RT increases in patients with urothelial carcinoma. Concurrent ADC–RT and toxicity. Patient # Toxicity Grade Toxicity History Relationship to RT 1 G3 skin Out of RT field Unlikely 2 G3 neuropathy Out of RT field Unlikely 3 G3 neuropathy Out of RT field Unlikely 4 G3 neuropathy Out of RT field Unlikely 5 G3 neuropathy Out of RT field Unlikely 6 G3 pneumonitis Out of RT field Unlikely 7 G3 skin Out of RT field Unlikely 8 G3 thrombocytopenia Began prior to RT Unlikely 9 G3 oral mucositis Out of RT field Unlikely 10 G5 neutropenia vs. pneumonitis 1 week after completing craniospinal irradiation, ADC infusions resumed; two weeks later, the patient was admitted for pneumonia Possible ADC: Antibody-drug conjugate; RT: Radiotherapy.
Choice of androgen receptor pathway inhibitors (ARPi) by disease volume and timing of metastases in metastatic hormone sensitive prostate cancer (mHSPC).
184 Background: We update evidence on mHSPC when new evidence becomes available (PMID: 36862387). ARANOTE trial prompted us to assess the comparative efficacy of darolutamide (DARO) with other ARPi agents in mHSPC using the living network meta-analysis (LNMA). Methods: This LNMA is conducted using the living interactive evidence (LIvE) synthesis framework. Phase III trials assessing systemic treatments in mHSPC are included. Mixed treatment comparisons were made using a frequentist network meta-analysis. P-scores were computed to assess relative treatment rankings with higher values indicating potentially better efficacy. Results: This report of LNMA includes a total 11 trials (12628 patients; 12 unique treatment options) as of October 1 st , 2024. Overall results were consistent with prior updates. Analysis limited to the ARPi trials showed that inhigh volume, abiraterone acetate (AAP)+androgen deprivation therapy (ADT) (HR: 0.46; 95% CI: 0.40-0.53; rank 1), apalutamide (APA)+ADT (0.53; 0.41-0.68; rank 3), DARO+ADT (0.60; 0.44-0.81; rank 4) and enzalutamide (E)+ADT (0.48; 0.41-0.56; rank 2) significantly improved radiographic progression-free survival (rPFS) compared to ADT alone. No statistically significant differences were observed with DARO+ADT compared to AAP+ADT (1.30; 0.94-1.82), APA+ADT (1.14; 0.77-1.67) and E+ADT (1.24; 0.89-1.79). Inlow volume, AAP+ADT (0.48; 0.37-0.63; rank 4), APA+ADT (0.36; 0.22-0.58; rank 3), DARO+ADT (0.30; 0.15-0.60; rank 1) and E+ADT (0.32; 0.25-0.41; rank 2) significantly improved rPFS compared to ADT. E+ADT significantly improved rPFS compared to AAP+ADT (0.67; 0.47-0.96) in low volume. No statistically significant differences were observed with DARO+ADT compared to AAP+ADT (0.62; 0.30-1.30), APA+ADT (0.83; 0.36-1.92) and E+ADT (0.93; 0.45-1.94). In synchronous disease, AAP+ADT (0.58; 0.51-0.67; rank 4), APA+ADT (0.49; 0.39-0.62; rank 2), DARO+ADT (0.59; 0.44-0.79; rank 3) and E+ADT (0.42; 0.36-0.50; rank 1) significantly improved rPFS compared to ADT. E+ADT significantly improved rPFS compared to AAP+ADT (0.73; 0.59-0.89) in synchronous disease. In metachronous disease, DARO+ADT (0.34; 0.17-0.67; rank 1), APA+ADT (0.41; 0.22-0.77; rank 2) and E+ADT (0.44; 0.35-0.57; rank 3) significantly improved rPFS compared to ADT. No statistically significant differences were observed with DARO+ADT compared to APA+ADT (0.83; 0.33-2.08) and E+ADT (0.76; 0.37-1.57) in metachronous disease. The results were consistent for overall survival. Conclusions: Current evidence suggests no significant differences for darolutamide as compared to other ARPi agents. Enzalutamide may be preferred over AAP in low-volume or synchronous disease. Given similar efficacy, choice of ARPi requires careful consideration of patient-specific factors including cost, accessibility and toxicity.
A comprehensive evaluation of gene expression-based signatures for detecting tertiary lymphoid structures (TLS) in metastatic renal cell carcinoma (mRCC).
591 Background: TLS are organized lymphoid aggregates linked to improved response to immunotherapy in multiple cancers, including mRCC. Traditionally, TLS assessment relies on pathological staining of tumor sections. In this study, we evaluated the performance of TLS gene-expression signatures as an alternative diagnostic tool. Methods: Primary tumors from treatment-naïve patients with mRCC in the HCRN GU16-260 trial were analyzed using multiparametric immunofluorescence (IF), staining for CD3, CD20 (TLS), CD21 (mature TLS), and CD8. The counts and densities of total and mature TLS were calculated. Bulk RNA sequencing was performed on the same specimens, and 4 gene signature scores (Meylan, Cabrita, Coppola, and Ng) were estimated using gene set variation analysis (GSVA). Spearman's correlations between signature scores and TLS IF parameters, as well as the area under the receiver operator characteristic (AUROC) curve, were computed. Results: Our cohort included 78 patients with matched IF and RNA-seq data. All 4 TLS signatures demonstrated strong predictive performance for detecting the presence (vs. absence) of TLS by IF in each sample (AUROC 0.8 to 0.85). Quantitatively, the 4 TLS signature scores, measured as continuous variables, correlated with IF-based counts and densities of total TLS, and to a lesser extent, mature TLS (Table). In terms of comparative performance, Meylan’s signature showed the highest correlation with IF TLS features, while Ng’s was the least correlated (Table). Furthermore, Meylan’s signature achieved the best predictive ability to stratify high vs. low TLS (AUROC 0.83) and was more specifically correlated with TLS compared to CD8 density (Table). Conclusions: Expression-based signatures exhibit robust predictive ability for TLS detection and quantification, similar to previously established CD8 signatures, and represent valid surrogate tools to complement pathological diagnosis. Spearman’s correlations between IF parameters and TLS signatures. Parameter Meylan Cabrita Coppola Ng Total TLS count ρ=0.65, P= 1.1x10 -10 ρ=0.58, P= 2.9x10 -8 ρ=0.56, P= 7.1x10 -8 ρ=0.42, P= 1.4x10 -4 Mature TLS count ρ=0.51, P= 2.1x10 -6 ρ=0.41, P= 1.8x10 -4 ρ=0.34, P= 2.3x10 -3 ρ=0.39, P= 5.0x10 -4 Total TLS density ρ=0.63, P= 6.1x10 -10 ρ=0.58, P= 3.4x10 -8 ρ=0.55, P= 2.2x10 -7 ρ=0.42, P= 1.4x10 -4 Mature TLS density ρ=0.49, P= 5.1x10 -6 ρ=0.39, P= 3.5x10 -3 ρ=0.32, P= 4.3x10 -3 ρ=0.38, P= 6.8x10 -4 CD8 density ρ=0.42, P= 3.1x10 -4 ρ=0.62, P= 2.1x10 -8 ρ=0.67, P <2.2x10 -16 ρ=0.35, P= 2.9x10 -3
Upstaging and risk migration with blue light cystoscopy for non–muscle-invasive bladder cancer: Results from a prospective multi-center registry.
686 Background: Blue-light cystoscopy (BLC) is an established procedure for use in the diagnosis and surveillance of patients with non-muscle-invasive bladder cancer (NMIBC). It is associated with improved detection rates compared to white light cystoscopy (WLC); however, limited data is available regarding its role in upstaging and/or upgrading when used alongside WLC. The aim of this study is to assess the incidence and features of patients undergoing upstaging and/or risk-group migration with the implementation of BLC. Methods: Using data from the prospective multi-institutional Cysview Registry (2014-2024), patients with NMIBC who underwent transurethral resection or biopsy of bladder tumors were identified. The patients in whom malignant lesions were exclusively detected by BLC, as well as those experiencing an upward change in risk category (as defined by the American Urological Association [AUA] classification) based on BLC findings, were documented. The clinical features of these patients were subsequently reviewed. Results: In this study, 2,854 patients were enrolled, who collectively underwent 4,158 resections and provided 6,432 separate pathology samples. A total of 201 (7%) patients had at least one malignant lesion detected exclusively by BLC while having negative WLC. These lesions (total 335) included carcinoma in-situ (CIS) in 145 (43%), low-grade Ta in 53 (16%), high-grade Ta in 95 (28%), high-grade T1 in 37 (11%), and high-grade T2 in 5 (1%). In patients with multifocal disease, BLC resulted in AUA risk-group upward migration in 66 (2.3%) patients.Theclinical features of these two groups are presented in the table. Taken together, the total rate of upgrading or upstaging using BLC was 9.3%, including migration to low-risk in 1.2%, intermediate-risk in 2.1%, and high-risk in 6%. Conclusions: Using BLC during transurethral resection or biopsy of bladder tumors results in risk group migration in over 9% of patients with NMIBC. This impacts patient management, including the administration of intravesical therapy when it was not initially planned, an extension in the duration of therapy, or the decision to proceed with radical cystectomy. Clinical features of patients with malignant lesions detected by BLC only (A) and those with risk group migration (B). Clinical features A B Age, median (IQR), year 71 (63-76) 71 (61-77) Gender, n (%) Male Female 140 (74)49 (26) 54 (82)12 (18) History of smoking, n (%) 117 (62) 40 (61) Primary occurrence, n (%) 65 (34) 14 (21) History on intravesical therapy, n (%) 92 (49) 40 (61) Urine cytology * , n (%) Positive Suspicious Atypical Negative/NA 33 (17)21 (10)41 (20)106 (53) 13 (20)7 (11)10 (15)36 (54) IQR: interquartile range; NA: not available. *Detected by either voided urine or bladder wash.
Clinical and radiographic trends in patients with renal angiomyolipomas (AML).
458 Background: Renal angiomyolipoma (AML) is a common benign solid tumor of the kidney, typically found incidentally through imaging. These tumors can also present with symptoms like flank pain, hematuria, or retroperitoneal bleeding. AMLs are usually monitored and treated when they reach sizes between 4 and 6 cm based on clinical judgment, although the timing for intervention remains debated. This study aimed to investigate growth rates, assess radiographic features, and evaluate trends in clinical presentation. Methods: This multicenter, single-institution retrospective study reviewed patients diagnosed with renal AML at three Mayo Clinic locations (Rochester, Arizona, Jacksonville) from 1997 to 2021. Eligible patients had at least three abdominal scans over a minimum of two years and 36 months of follow-up. We reviewed radiologic reports, images, and charts to record demographics, tumor characteristics, imaging modalities, intervention rates, tumor sizes, and growth rates. The Mann-Whitney and Fisher exact tests were used for comparisons. Results: Among 839 patients, most were female (81.6%), with a median age of 58.55 years. Bleeding patients had significantly larger initial tumors (median 6.50 cm) compared to non-bleeding patients (median 1.20 cm), p < 0.001. Treatment with everolimus was more common in bleeding patients (12.2% vs. 2.1%), and the prevalence of tuberous sclerosis was higher in the bleeding group (19.5% vs. 6.3%). All bleeding patients underwent intervention, while 22.3% of the overall cohort received treatment. Follow-up duration and total scans did not differ significantly between groups. Over 12 months, non-bleeding patients had a median growth change of 0.00 cm [IQR: 0.00, 0.30], whereas bleeding patients showed a median growth change of 0.40 cm [IQR: 0.15, 1.00], p = 0.002. Conclusions: This study reveals significant differences in characteristics and growth patterns of renal angiomyolipomas between bleeding and non-bleeding patients. Bleeding patients had larger initial tumors and greater growth changes over time. Further studies on radiographic features may help identify lesions needing earlier intervention. Demographic and clinical characteristics of patients with renal AML: Comparison bleeding vs non-bleeding groups. Overall Non-bleeding Bleeding P-Value N 839 798 41 Gender (%) Female 685 (81.6) 650 (81.5) 35 (85.4) 0.793 Male 152 (18.1) 146 (18.3) 6 (14.6) Unknown 2 (0.2) 2 (0.3) 0 (0.0) Age (median [IQR]) 58.55 [47.04, 66.95] 58.72 [47.32, 67.19] 53.84 [42.88, 60.82] 0.015 Follow up (months) (median [IQR]) 45.30 [37.12, 89.15] 46.45 [36.32, 89.52] 39.70 [36.30, 61.63] 0.233 Total scans (median [IQR]) 3.00 [3.00, 5.00] 4.00 [3.00, 5.00] 3.00 [3.00, 4.00] 0.282 Initial size (cm) (median [IQR]) 1.30 [0.80, 2.70] 1.20 [0.70, 2.50] 6.50 [3.00, 9.30] <0.001 Everolimus (%) Yes 22 (2.6) 17 (2.1) 5 (12.2) 0.001 Tuberous sclerosis (%) Yes 58 (6.9) 50 (6.3) 8 (19.5) 0.003 Intervention (%) Yes 187 (22.3) 147 (18.4) 41 (100) <0.001
A retrospective real-world study of disitamab vedotin combined with tislelizumab versus chemotherapy in patients with previously untreated metastatic urothelial carcinoma.
733 Background: Eligible patients with metastatic urothelial carcinoma (mUC) typically receive platinum-based chemotherapy as first-line therapy. Recently, antibody-drug conjugates (ADCs) combined with PD-1 antibody have shown good efficacy and safety in metastatic urothelial carcinoma (mUC). And HER2-positive thought to be an unfavorable prognostic factor and associated with poor outcomes but can benefit from anti-HER2 ADCs such as Disitamab Vedotin (RC48-ADC). The aim of this retrospective study is to evaluate the efficacy and safety of RC48-based therapy in real-world untreated mUC, especially in comparison to standard chemotherapy. Methods: We retrospectively collected data from 70 consecutive patients with mUC who received routine care between July 2022 and December 2023 including 30 received RC48-ADC plus Tislelizumab (DT-group) and 40 received the conventional regimen of Gemcitabine plus Cisplatin (GC-group). Last follow-up on 30 March 2024. The primary endpoints were objective response rate (ORR), disease control rate (DCR), median progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs). Results: The median age of the DT-group and GC-group patients were 67-y and 64-y, with 66.7% (n=20) and 82.5% (n=33) HER-2 negative (identified as IHC 0 or 1+). Baseline characteristics of the two groups, including age, gender, pathological grading, ECOG score, tumour location, metastasis and HER-2 expression showed no statistically difference (P > 0.05). The ORR in DT-group was 1.5 times higher than in GC-group, reaching 73.3% (22/30) versus 47.5% (19/40) with a higher CR rate (20% vs 0%). Even in HER-2 negative subgroup from DT-group, the RC48-ADC plus Tislelizumab therapy achieved impressive outcomes (ORR 55% (11/20)) comparable to chemotherapy. For survival analyses, PFS was longer in the DT-group than in GC-group (median, 10.98 months vs. 7.67 months; P<0.005), as was OS (median, not reached vs. 11.34 months). Two groups showed a similar safety profile (p > 0.05). The most reported TRAEs were bone marrow suppression, gastrointestinal and hepatobiliary disorders, malaise, alopecia and rash, and no ≥ grade 3 TRAEs or treatment-related deaths were reported. Conclusions: This retrospective study of patients with treatment-naïve mUC demonstrated administration of RC48 for real-world patients is both effective and safe. Several global clinical trials (DV-001, RC48-G001) evaluating efficacy and safety of RC48-ADC in combination with immunotherapy are ongoing. These data further solidify the benefit of anti-HER2 ADC combined with checkpoint inhibitors for frontline treatment of patients with mUC.
Impact of relative dose intensity on efficacy of enfortumab vedotin monotherapy in platinum and ICI resistant metastatic urothelial carcinoma: A multi-institutional real-world analysis.
728 Background: The treatment paradigm for metastatic or locally advanced urothelial carcinoma (mUC) has shifted towards combination therapies with Enfortumab Vedotin (EV) and Pembrolizumab. Understanding EV's characteristics is crucial for optimizing treatment. The EV-101 trial showed a correlation between exposure and efficacy, but few real-world studies explore how relative dose intensity (RDI) impacts outcomes. This study examines RDI's effect on efficacy using real-world data. Methods: We retrospectively analyzed 123 mUC patients treated with EV monotherapy as third-line or later, following progression after platinum-based chemotherapy and resistance to immune checkpoint inhibitors (ICIs). Data were collected from five institutions. We evaluated overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Patients were grouped into full dose on-schedule (FDO) and dose/schedule adjusted (DSA) based on EV dose and timing until best response (BR). On DSA group, relative dose intensity (RDI) until BR (BRRDI) was measured, and patients were classified into High (BRRDI > 80), Intermediate (80 ≥ BRRDI > 70), and Low (BRRDI ≤ 70) groups for comparison. Results: Among the 123 patients, median OS (mOS) was 14.8 Ms, median PFS (mPFS) was 7.1 Ms, and ORR was 48%, with a complete response (CR) rate of 9%. In the FDO group (31 patients), mOS was 9.3 Ms, mPFS was 4.5 Ms, and ORR was 29% (CR: 0%). In the DSA group (93 patients), mOS was 17.1 Ms (p=0.002), mPFS was 8.8 Ms (p=0.019), and ORR was 56% (CR: 12.1%) (p=0.0029 for ORR, p=0.017 for CR). In the BRRDI analysis, median time to BR was 2.6 Ms. ORR for High, Intermediate, and Low groups were 50% (CR: 20%), 58% (CR: 3.4%), and 63% (CR: 9.4%), respectively, with significant differences in CR (p=0.026). Conclusions: Patients requiring dose or schedule adjustments before best response showed better ORR, OS, and PFS than those on full dose. Higher BRRDI correlated with better CR, emphasizing the need to manage adverse events while maintaining dose intensity until BR.
Association of statin use with overall survival and cardiac adverse events in patients with advanced prostate cancer treated with apalutamide: A pooled analysis of TITAN and SPARTAN.
137 Background: The impact of statins on overall survival (OS) in patients (pts) with advanced prostate cancer is not fully understood. We performed a pooled analysis of the TITAN and SPARTAN trials to determine if exposure to statins had an independent effect on OS and grade ≥3 cardiac adverse events (AE) in pts treated with androgen deprivation therapy (ADT) with/without apalutamide (APA). Methods: TITAN and SPARTAN randomized pts to receive ADT with/without APA either in metastatic hormone-sensitive or in non-metastatic castration-resistant prostate cancer, respectively. Pts had at least some duration of statin exposure during the assigned treatment which could have started before and ended during or after the assigned treatment. A stratified (for the trial) multivariable Cox proportional hazard model was applied to determine the association of statin use with OS. Adjusted (adj) OS was estimated for pts in each trial, separately. A multivariable stratified logistic regression model was applied to determine the association of statin exposure with grade ≥3 cardiac AE. Results: Out of 2190 pts included in this study, 1288 received APA (TITAN 517; SPARTAN 771) and 484 were exposed to statins. Statin exposure was associated with significantly superior OS among all APA-treated pts (adjusted hazard ratio [HR]: 0.58; 95% CI: 0.45-0.75) while the OS benefit was not significant among ADT-treated pts (adjusted HR: 0.83 [0.62-1.11]). Adjusted 3-year OS in pts with and without statins were 82% and 67% (adjusted difference: 15%; 95% CI: 6-24) in the APA arm of TITAN and 86% and 78% (adjusted difference: 8% [3-13]) in the APA arm of SPARTAN. Adjusted 3-year OS among pts with and without statins was 71% and 58% (adjusted difference: 13% [3-24]) in the ADT arm of TITAN and 77% and 75% (adjusted difference: -2% [-10 to 6]) in the ADT arm of SPARTAN. Statin exposure was associated with a higher risk of grade ≥3 cardiac AE in pts treated with APA (adjusted odds ratio [OR]: 2.92 [1.56-5.47]) and ADT (adjusted OR: 3.06 [1.18-7.89]). Conclusions: In this exploratory analysis, exposure to statins was associated with significantly improved OS in all APA-treated patients but not in ADT-treated patients. Statin exposure was also associated with a higher risk of grade ≥3 cardiac AE in all pts (APA and ADT), which could be attributed to pre-existing cardiac comorbidities requiring these patients to start statin.
Association between abnormal IMDC laboratory criteria after surgery and cancer-specific and overall survival in non-metastatic renal cell carcinoma: Potential biomarkers for adjuvant therapy patient selection.
567 Background: The International Metastatic RCC Database Consortium (IMDC) criteria are widely used for risk stratification in metastatic renal cell carcinoma (RCC), but their role in non-metastatic RCC is less defined, especially as a biomarker of recurrence. This study seeks to evaluate (1) the prevalence of IMDC abnormalities in non-metastatic RCC patients (nmRCCC), (2) the impact of nephrectomy on the normalization of these criteria, and (3) the association between post-operative IMDC abnormalities and oncological outcomes. Methods: Data from the Canadian Kidney Cancer Information System (CKCis) were analyzed to identify non-metastatic RCC patients diagnosed between January 2011 and April 2024 who underwent nephrectomy after diagnosis. Laboratory tests were evaluated preoperatively (within 6 months before surgery) and postoperatively (between 2 and 15 months). Univariable and multivariable analyses were performed to assess the association with overall survival, recurrence-free survival, and cancer-specific survival. Results: A total of 1,804 patients were analyzed, with 65.7% male and mean age was 62.5y. Tumors pathological characteristics were: pT1 (69.2%), pT2 (5.6%), pT3 (1.8%), pT4 (0.28%); tumors necrosis (21.8%); mean tumor size (4.7cm) and clear cell carcinoma (73.1%). Preoperative hemoglobin (Hb), neutrophils, platelets (Plt), and corrected calcium (Ca 2+ ) IMDC criteria abnormalities were identified in 19.4, 9.6, 4.3, and 3.2% of patients, respectively. After surgery, 45.4, 79.8, 80.4, and 76.9% of these abnormal cases normalized, respectively. Among patients with normal preoperative Hb, neutrophils, Plt, and Ca 2+ , 9.65, 4.4, 1.0, and 1.6% developed postoperative IMDC criteria abnormalities, respectively. In multivariate analysis, patients with normal Hb, neutrophils, and Ca 2+ , both pre- and postoperatively, had an increase in overall survival (OS) compared to those with abnormal postoperative values. Hazard ratios (HR[95%CI]) for increased OS were 3.6[2.8-4.7], 2.1[1.7-2.7] and 3.5[1.5-43.1], respectively, compared to those with abnormal postoperative values. Furthermore, those with normal Hb, neutrophils, Plt, and Ca 2+ , both pre- and postoperatively, had an increase in cancer-specific survival (CSS) with HR of 3.3, 4.3, 8.0 and 5.7 (p<0.05),indicating a significantly higher CSS probability than patients with abnormal postoperative values. Conclusions: Abnormal IMDC laboratory criteria are frequently found in nmRCC, especially anemia, and most normalize after surgery. Finding abnormal IMDC laboratory criteria post-surgery is associated with decreased CSS and OS. This knowledge may be useful in stratifying patients for intensified monitoring or for future adjuvant therapy clinical trials.
Apatinib monotherapy for pretreated advanced squamous cell carcinoma of the penis: A phase II trial.
8 Background: Treatment options for patients with advanced penile squamous cell carcinoma who have disease progression on systemic chemotherapy are scarce. Antiangiogenic drugs have shown antitumor effects in case series. This phase 2 trial evaluated the activity and safety of apatinib (a VEGF receptor inhibitor) in such patients. Methods: This investigator-initiated, single-arm, phase 2 trial was performed at a tertiary cancer center in Shanghai, China. Eligible patients had histologically confirmed penile squamous cell carcinoma, were not candidates for surgery with curative intent, had measurable disease, and had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Patients were prescribed oral apatinib 500 mg daily with the option of dose reduction to manage adverse events. The primary endpoint was the investigator-assessed overall response rate (ORR) assessed in all patients who received at least one dose of study drug. Results: Between 2016 and 2023, we enrolled 23 patients, all of whom received at least one dose of study treatment. Of the 23 patients, sixteen had an ECOG performance status of 2. Only six patients had human papillomavirous-positive tumors. Five patients had a partial response (ORR=22% (95%CI: 10%-42%). Median Progression-Free Survival was 3.8 months and median overall survival was 7.2 months. Treatment-related adverse events of grade 3 or worse occurred in 7 (30%) of 23 patients. The most common grade 3 or 4 treatment-related adverse events were hand–foot syndrome (13%), hypertension (9%), and increase in serum alanine aminotransferase (ALT:9%). No treatment-related deaths occurred. Conclusions: Apatinib in pretreated advanced penile cancer showed limited efficacy with a manageable safety profile. A prospective study with apatinib in combination with immune checkpoint therapy is ongoing. Clinical trial information: 000021849.
A phase 2 trial of neoadjuvant futibatinib plus durvalumab for cisplatin-ineligible patients with <i>FGFR</i> overexpressing muscle-invasive bladder cancer.
TPS899 Background: There is an unmet need to develop neoadjuvant therapies for cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC). Neoadjuvant immune checkpoint inhibition (ICI) has shown promising early results in this population; however, > 2/3 pts did not achieve pathological complete response (pCR), a surrogate endpoint for improved survival. Fibroblast growth factor receptor inhibitor (FGFRi) may induce synergy with ICI through modulation of the tumor immune microenvironment. FGFR mRNA overexpression by RNA in situ hybridization (ISH) is an emerging biomarker that may predict responses to an FGFRi ± ICI. Futibatinib (FUTI) is an irreversible pan-FGFRi, and durvalumab (DURV) is an anti-PD-L1 antibody. Methods: This is a phase 2, single arm, multicenter study to evaluate the efficacy and safety of neoadjuvant FUTI + DURV before cystectomy. Pts with stage cT2 to cT4aN0M0, urothelial carcinoma predominant histology, cisplatin-ineligible by Galsky criteria, and FGFR1-3 mRNA expression ≥3+ by RNAscope ISH assay are eligible. Twenty-four pts will be treated with FUTI 20 mg PO daily and DURV 1500 mg IV on day 1 of every 28-day cycle for 3 cycles. The primary outcome is pCR (defined as ypT0N0). We hypothesize that FUTI + DURV will improve the pCR rate from 21% to 41%. This trial has 80% power to detect the alternative hypothesis while maintaining a one-sided α = 0.1. The study will begin with a safety lead-in period, during which 6 pts will be enrolled for dose-limiting toxicity (DLT) evaluations. After confirming safety (≤ 2 DLTs), another 18 pts will be enrolled. The study will be monitored for futility using a Bayesian Optimal Phase II design, including 2 interim analyses (12 and 18 pts). If there are ≥ 3 pCRs among the first 12 pts, we will continue enrollment. If there are ≥ 5 pCRs among the first 18 pts, the study will continue. When 24 evaluable pts are enrolled, we will reject the null hypothesis and conclude that the treatment is acceptable if there are ≥ 8 pCRs. The secondary endpoints include safety, pathologic downstaging rate, progression-free survival, and overall survival. Correlative studies will explore immune and molecular predictors of response and resistance in the tumor, blood, and urine. Clinical trial information: NCT06263153 .
Efficacy and safety of CAR-T cell therapy in penile and urethral carcinomas: A meta-analysis of preliminary clinical trials and case studies.
655 Background: Penile and urethral carcinomas are rare and aggressive cancers with limited treatment options, often leading to poor prognoses. Chimeric Antigen Receptor T-cell (CAR-T) therapy has shown promise in various malignancies, but its efficacy and safety in penile and urethral carcinomas remain under-explored. This meta-analysis aims to evaluate the preliminary clinical trials and case studies on CAR-T cell therapy in treating these rare carcinomas. Methods: The PubMed, Embase, Scopus and Cochrane databases were systematically searched from inception until June 2024 using relevant keywords. We performed proportional meta-analysis of untransformed proportions using Random Effects model in OpenMeta (version 5.3). The I 2 and X 2 statistics were used to evaluate inter-study heterogeneity. An I 2 value of >50% was considered significant heterogeneity. Subgroup analyses were performed to identify factors influencing treatment outcomes. Results: A total of 15 studies, including 10 clinical trials and 5 case reports, comprising 230 patients were included in the meta-analysis. The pooled overall response rate (ORR) was 42% (95% CI: 30%-55%), with a complete response rate (CRR) of 15% (95% CI: 8%-25%). Common adverse effects included cytokine release syndrome (CRS) (35%) and neurotoxicity (20%). Pre-existing comorbidities and prior treatments were significant factors affecting outcomes. No treatment-related mortality (TRM) was reported. Conclusions: CAR-T cell therapy demonstrates encouraging efficacy in penile and urethral carcinomas, with manageable safety profiles. While preliminary results are promising, larger and more comprehensive studies are needed to validate these findings and optimize treatment protocols.
Inclusion of patients with reduced performance status (ECOG 2 or higher) in FDA registrational trials for renal cell carcinoma (RCC).
453 Background: Clinical trials often use performance status indicators to include only those participants with good baseline functional status. The Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) and the Karnofsky Performance Scale (KPS) are two such scales that determine a cancer patient’s ability to perform common tasks. As a result, the study population does not accurately represent the real-world population. We evaluated the inclusion of patients with ECOG 2 or greater/ KPS less than 70 in RCC clinical trials leading to FDA approvals between 2014 and 2024. Methods: The US Food and Drug Administration (FDA) approvals for drugs approved in RCC and associated clinical evidence were collected from the FDA website from 2014-2024. Data from each registrational trial was searched in public databases using drug name, trial name, and registration number. The total number and percentage of participants in each ECOG/KPS category were recorded and analyzed. Results: The FDA approved 13 drugs and combinations for the treatment of RCC from 2014 - 2024. A cumulative total of 8731 participants were included in these trials, with only 24 (0.3%) participants with ECOG PS 2 or greater (KPS <70). Only 3 of the 13 trials included participants with ECOG 2 (KPS <70) with 2 trials having <1% ECOG 2 participants. Only CABOSUN trial had >10% enrolment of ECOG 2 participants. There was no participation of ECOG 3 in any of the trials. Of the total participants, over 70% belonged to ECOG score 0 or KPS 90-100 (excluding CheckMate 214 for which PS distribution data was unavailable). Conclusions: There is poor enrollment of participants with ECOG 2 and greater in registrational clinical trials for RCC. This limits the therapeutic options available for patients with poor PS and is not representative of the real-world population. Greater inclusion of poor PS patients is needed in future trials. Percentage enrollment of patients with reduced PS in registrational trials for RCC. Clinical trial Year Reduced PS% (ECOG 2 or higher/KPS <70) CABOSUN 2017 12.7% S-TRAC 2017 0.2% CheckMate 025 2015 0.4% LITESPARK-005, KEYNOTE-564, TIVO-3, CLEAR, CHECKMATE-9ER, JAVELIN Renal 101, KEYNOTE-426, CheckMate 214, METEOR, Lenvatinib+Everolimus 2016-2023 0.0%
Patterns of hospital admissions and readmissions due to immune-related adverse events in patients with genitourinary cancers.
462 Background: Immune checkpoint therapies (ICTs) improve survival in patients with genitourinary (GU) cancers, specifically renal cell carcinoma (RCC) and urothelial carcinoma (UC). However, they also lead to inflammation of normal host organs: immune-related adverse events (irAEs). Severe irAEs may lead to repetitive hospitalizations especially if refractory which affects patients’ ability to receive further anti-cancer therapy. We reasoned that identifying such irAEs may enable clinical quality improvement interventions to improve outcomes. Methods: All consecutive patients hospitalized under the Genitourinary Medical Oncology inpatient service at The University of Texas MD Anderson Cancer Center with irAEs over a 14-month period (June 2023 to August 2024) were evaluated. Readmission was defined as re-entry to any hospital within 30 days of an initial discharge. Patient characteristics, ICT regimens, irAE types, treatment strategies, time to outpatient follow-up, and clinical outcomes were analyzed. Results: Sixty-seven patients (n=53 male; n=14 female) were admitted at least once for an irAE. The median age was 69 years (IQR: 62.0-75.5). Male predominance was consistent with the sex distribution of the cancers included (RCC, n=42, 63%; UC, n=11, 16%; prostate cancer, n=11, 16%). Gastroenterology-related irAEs were the most common cause of hospitalization, accounting for 45% (30/67) of admissions, primarily due to colitis (n=18) and hepatitis (n=9). Among these cases, 7% (2/30) were classified as grade 4, 80% (24/30) as grade 3, and 13% (4/30) as grade 2. Readmission occurred in 28% (19/67) of patients. Of the readmissions, 42% (8/19) were due to irAEs, 37% (7/19) to non-ICT-related reasons (e.g., disease progression, edema, pulmonary embolism), and 21% (4/19) to infection. Among the 8 readmissions for irAEs, 75% (6/8) were classified as grade 3 and 25% (2/8) as grade 2. Of these, 5 readmissions were attributed to the recurrence of the same irAE (colitis, n=3; hepatitis, n=2). These cases of recurrent irAEs resulted in delayed anti-cancer therapy for a median of 49 days (IQR: 42-57.5). Furthermore, readmissions were potentially preventable in 3 cases (colitis, n=2; hepatitis, n=1) due to delays in initiating biologic therapy, while the remaining 2 cases were associated with delays in outpatient follow-up. Conclusions: In this single-department, single-center case series, gastroenterology-related irAEs were the most common cause of irAE-related admissions and readmissions in patients undergoing ICT therapy for GU cancers. Quality improvement efforts to reduce readmission are ongoing at our institution including: (1) Improving clinical education for early detection of symptoms; (2) Shortening time to post-discharge outpatient follow-up; and (3) Optimizing timing and usage of steroid-sparing biologic therapies.
Systemic therapies in renal cell carcinoma with brain metastases: A comparative meta-analysis of immunotherapy and tyrosine kinase inhibitors.
559 Background: Renal cell carcinoma (RCC) with brain metastases presents a clinical challenge. Management remains unclear, as systemic therapy data are limited and many trials exclude patients with active brain metastases. Current treatment primarily involves CNS-targeted radiation (e.g., stereotactic radiosurgery and whole-brain radiation therapy), while systemic therapies like tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) are underexplored. This meta-analysis evaluates the efficacy of systemic treatments and whether these patients should continue to be excluded from clinical trials. Methods: A systematic search of PubMed, CENTRAL, MEDLINE, and Google Scholar was conducted through October 2024, focusing on studies of mRCC patients with brain metastases treated with ICIs, TKIs, or their combination. ICI therapies included nivolumab, ipilimumab, pembrolizumab, atezolizumab, and avelumab, while TKIs included sorafenib, sunitinib, and cabozantinib. Case reports, ongoing trials, narrative reviews, and meta-analyses were excluded. Primary endpoints were complete response (CR), partial response (PR), objective response rate (ORR), and overall survival (OS). Statistical analyses used fixed/random-effects models based on heterogeneity. Results: Nineteen studies involving 947 mRCC patients with brain metastases were included. The pooled analysis showed an ORR for ICIs of 29.9%, with a CR of 3.4% and PR of 28.9%. Brain-specific ORR, CR, and PR for ICIs were 27.5%, 10.8%, and 17.9%. TKIs alone showed a pooled ORR of 11.7%, with a CR of 1.3% and PR of 11.6%. Brain-specific ORR, CR, and PR for TKIs alone were 38.1%, 6.9%, and 29.5%. Only one study reported on ICI-TKI combinations, with an ORR of 0%. Survival analysis showed significantly worse OS for brain metastasis patients treated with ICIs plus TKIs (HR: 2.06, p=0.001) and TKIs alone (HR: 2.51, p=0.02) compared to those without brain metastases. Conclusions: ICIs had superior overall response rates compared to TKIs and ICI-TKI combinations in mRCC patients with brain metastases. Brain-specific response rates were similar between ICIs and TKIs. Given the poor prognosis of brain metastasis patients treated with TKIs, further research is needed to determine if they should continue to be excluded from trials. Larger prospective studies are required to confirm these findings and optimize treatment.